There is a novel surgical procedure called renal denervation, which has been in development now for almost a decade, that could offer patients an alternative to taking hypertension drugs. This one-off procedure uses ultrasound to reduce blood pressure in patients with hypertension.
The reason the progress has been so slow, however, is due to inconsistent clinical trial results. But now, a promising new study by Queen Mary University of London and Barts Health NHS Trust is underway to document the long-term effects of this treatment and allow the procedure to finally be used to help people around the world.
Renal Denervation
Renal denervation involves delivering ultrasound pulses to nerves in the walls of renal arteries. It targets the nerves connected to the kidneys. The procedure has been found to reduce (and maintain reduced) blood pressure in hypertension patients for at least six months, particularly in cases where hypertension has not effectively responded to traditional medications.

The Study
This study is not the first phase of research on the surgery. It is a follow-up on an earlier report that chronicled the effects of the surgery on patients up to two months after the initial procedure. The most recent research (the one that is being described below) was published in the journal Circulation.
The Research
- They followed over 140 patients for six months following the one-off renal denervation procedure.
- The patients were split into treatment and placebo groups, both groups still consuming some degree of antihypertensive medicines.
The Results
- After six months, 58 percent of the treatment group reported normal blood pressure control, compared to 42 percent of the placebo group.
- Over 35 percent of subjects receiving the ultrasound treatment were completely free of any blood pressure medications six months after the procedure.
- The six-month follow-up reported no significant adverse events from the surgical procedure, suggesting it is safe and tolerated well by patients.
Conclusion
To confirm the broad efficacy of the procedure the researchers will need to conduct larger trials. However, these early results show promise the ultrasound treatment could become an important new tool in the battle against hypertension.
Melvin Lobo, principal investigator on the trial, from Queen Mary University of London, said:
“These results point towards an exciting future for this new technology. If long-term safety and efficacy is proven in larger trials which are currently under way, we hope that renal denervation therapy could soon be offered as an alternative to many lifelong medications for hypertension.”
